Merck, Huma Therapeutics collaborate to develop digital solution for cancer patients
London: Huma Therapeutics, a global digital health company, and Merck KGaA, Darmstadt, Germany, a science and technology company, have announced a partnership to develop a digital solution that aims to help cancer patients better understand and manage their conditions and treatment. The Cross-Indication Disease Management Platform will be made available to patients being treated with Merck KGaA, Darmstadt, Germany's cancer therapies.
Set for initial launch in 2024, the preliminary direct-to-patient solution will support urothelial carcinoma patients in the UK.
Regulated platform will drive improved treatment adherence
Utilising Huma's disease-agnostic Software as a Medical Device (SaMD) technology platform, the first of its kind to achieve both EU MDR Class IIb regulation and FDA Class 2 510(k) clearance, the collaboration between Huma and Merck KGaA, Darmstadt, Germany aspires to (with local specifications):
Read also: Merck bags USFDA nod for Keytruda plus gemcitabine, cisplatin to treat Biliary Tract Cancer
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.